WASF2 Serves as a Potential Biomarker and Therapeutic Target in Ovarian Cancer: A Pan-Cancer Analysis.

Yang, Xiaofeng; Ding, Yuzhen; Sun, Lu; Shi, Meiting; Zhang, Ping; He, Andong; Zhang, Xiaotan; Huang, Zhengrui; Li, Ruiman

Yang, Xiaofeng; Ding, Yuzhen; Sun, Lu; Shi, Meiting; Zhang, Ping; He, Andong; Zhang, Xiaotan; Huang, Zhengrui; Li, Ruiman.

Afiliación

Yang X; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Ding Y; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Sun L; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Shi M; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Zhang P; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
He A; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Zhang X; Department of Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Huang Z; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Li R; Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Front Oncol ; 12: 840038, 2022.

Article en En | MEDLINE | ID: mdl-35359421

Palabras clave

WASF2; biomarker; immune; pan-cancer; therapeutic

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google